Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Congenital Ichthyosis Clear all
Completed No phase listed Observational

National Registry for Ichthyosis and Related Disorders

NCT00074685
View directory record Official record
Conditions
Darier Disease, Hailey-Hailey Disease, Hyperkeratosis, Epidermolytic, Ichthyosis, Ichthyosis, Lamellar, Ichthyosis, X-Linked, Keratoderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 21, 2026, 9:31 PM EDT
Recruiting Phase 1 Interventional

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

NCT06137157
View directory record Official record
Conditions
Netherton Syndrome
Interventions
ATR12-351
Drug
Lead sponsor
Azitra Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

NCT04697056
View directory record Official record
Conditions
Ichthyosis
Interventions
Imsidolimab, placebo
Drug · Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 21, 2026, 9:31 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population

NCT01016106
View directory record Official record
Conditions
Atopic Dermatitis, Ichthyosis Vulgaris
Interventions
Buccal Swab
Genetic
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Not applicable Interventional

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

NCT03796052
View directory record Official record
Conditions
Ichthyosis, Pruritus
Interventions
Avena Sativa Skincare Regimen
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Jul 21, 2026, 9:31 PM EDT
Recruiting No phase listed Observational

Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)

NCT06669949
View directory record Official record
Conditions
Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Interventions
no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 21, 2026, 9:31 PM EDT
Completed No phase listed Observational

The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases

NCT00005660
View directory record Official record
Conditions
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment

NCT01903447
View directory record Official record
Conditions
Internalizing Psychopathologies (IPs) Depression and Anxiety
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT03041038
View directory record Official record
Conditions
Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Not applicable Interventional

Effect of Curcumin on Gut Microbiota in IBS

NCT03568513
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Curcumin, Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
10 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Jul 21, 2026, 9:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism

NCT05047354
View directory record Official record
Conditions
Smith Lemli Opitz Syndrome, CHILD Syndrome, Lathosterolosis, Desmosterolosis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297
View directory record Official record
Conditions
Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 21, 2026, 9:31 PM EDT
Not listed Phase 2 Interventional

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

NCT05735158
View directory record Official record
Conditions
Autosomal Recessive Ichthyosis
Interventions
KB105, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rancho Santa Margarita, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rimegepant 75 MG [Nurtec]
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 21, 2026, 9:31 PM EDT
Not listed Phase 1Phase 2 Interventional

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

NCT04047732
View directory record Official record
Conditions
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
Interventions
KB105
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Not applicable Interventional

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

NCT00680693
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness training, Psycho-educational support group for women with IBS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Jul 21, 2026, 9:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of Diseases With Salivary Gland Involvement

NCT02327884
View directory record Official record
Conditions
Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
4 Years to 100 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Recruiting Early Phase 1 Interventional

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

NCT05649098
View directory record Official record
Conditions
Skin Diseases
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris

NCT03173547
View directory record Official record
Conditions
Ichthyosis Vulgaris
Interventions
146-9251 cream, Vehicle cream
Drug
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • Plainfield, Indiana • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 1Phase 2 Interventional

ADX-629 Therapy for Sjogren-Larsson Syndrome

NCT05443685
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-629
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cheno Effect on Transit in Health and IBS-C

NCT00912301
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Sodium chenodeoxycholate (NaCDC), Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Jul 21, 2026, 9:31 PM EDT